NASDAQ: SNDXSyndax Pharmaceuticals Inc Stock
$19.08-0.72 (-3.64%)
Updated Aug 13, 2026
SNDX Price
$19.08
Fair Value Price
-$0.83
Market Cap
$1.70B
52 Week Low
$12.99
52 Week High
$25.59
P/E
-7.6x
P/B
112.84x
P/S
7.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$252.25M
Earnings
-$220.77M
Gross Margin
95.8%
Operating Margin
-70.71%
Profit Margin
-87.5%
Debt to Equity
45.6
Operating Cash Flow
-$221M
Beta
1.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SNDX Overview
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNDX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SNDX
Ranked#163 of 464
Ranked#163 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $110.51 | A | |
| $10.90 | A |
Be the first to know about important SNDX news, forecast changes, insider trades & much more!
SNDX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNDX ($19.08) is overvalued by 2,395.39% relative to our estimate of its Fair Value price of -$0.83 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SNDX ($19.08) is not significantly undervalued (2,395.39%) relative to our estimate of its Fair Value price of -$0.83 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNDX due diligence checks available for Premium users.
Valuation
SNDX fair value
Fair Value of SNDX stock based on Discounted Cash Flow (DCF)
Price
$19.08
Fair Value
-$0.83
Undervalued by
2,395.39%
SNDX ($19.08) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNDX ($19.08) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.6x
Industry
16.75x
Market
14.17x
SNDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
112.84x
Industry
5.71x
SNDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNDX's financial health
Profit margin
Revenue
$72.8M
Net Income
-$49.4M
Profit Margin
-67.8%
SNDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SNDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$703.7M
Liabilities
$688.6M
Debt to equity
45.6
SNDX's short-term assets ($675.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNDX's short-term assets ($675.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SNDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$30.3M
Investing
-$16.9M
Financing
$252.8M
SNDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNDX vs Biotech Stocks
Syndax Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.